Troy Medicare is an AI-driven, pharmacy-powered Medicare Advantage company headquartered in Charlotte, North Carolina. Founded in 2018, the company focuses on providing personalized Medicare health plans that utilize data and technology to enhance patient care. By collaborating with pharmacies and healthcare providers, Troy Medicare aims to improve health outcomes and ensure transparency in its offerings. The company's approach empowers healthcare providers to make a meaningful impact on patient health while also rewarding them for achieving positive results. Through its services, Troy Medicare seeks to create fair and accessible health plans tailored to individual needs.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections. Its lead product candidate, ibrexafungerp, is an innovative oral and intravenous medication aimed at treating various fungal infections, including vulvovaginal candidiasis and invasive candidiasis. Ibrexafungerp has successfully completed Phase 2 clinical trials for vulvovaginal candidiasis. The company collaborates with Merck Sharp & Dohme Corp. and R-Pharm, CJSC for the development and commercialization of ibrexafungerp. In addition to its antifungal efforts, SCYNEXIS engages in drug discovery and development across multiple therapeutic areas, including antibacterials and antivirals, and offers contract research solutions such as medicinal chemistry and cGMP manufacturing. Founded in 1999 and originally named SCYNEXIS Chemistry & Automation, Inc., the company rebranded to SCYNEXIS, Inc. in 2002 and is headquartered in Jersey City, New Jersey.
Humacyte, Inc. is a medical research and development company headquartered in Morrisville, North Carolina, established in 2004. The company specializes in creating human tissue-based products aimed at regenerative medicine and vascular surgery. Its core technology involves the design of acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to minimize the risk of rejection. These innovations are utilized to produce tissue-engineered grafts for patients requiring vascular repair or replacement, positioning Humacyte as a key player in addressing vascular diseases and enhancing surgical outcomes.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
Nasuni Corporation develops enterprise cloud file storage solutions for organizations worldwide. It offers Nasuni UniFS, a global file system built for the cloud to store, organize, protect, and share unstructured file data. The company’s Nasuni UniFS hybrid cloud platform integrates disparate, siloed point tools into a single as-a-service solution. It serves architecture, engineering and construction, financial services, healthcare, manufacturing, media and advertising, oil and gas, and public sector industries. Nasuni Corporation was founded in 2009 and is based in Boston, Massachusetts with additional offices in Reading, United Kingdom; Marlborough, Massachusetts; and Cary, North Carolina.
Over half of Americans live paycheck to paycheck. We’re trying to fix that, by building new financial services that make it easier to make ends meet, pay down debt, and save money. And we’re doing it as a transparent, straightforward business that only profits when our customers do, too. We partner with employers to offer Even as a benefit. Employers offer Even to their people; in return, employers save money because Even improves employee retention. Even is based in Oakland, California and Raleigh, North Carolina.
Clinical Ink, Inc. specializes in eSource and patient engagement solutions designed to enhance the efficiency of clinical research for sites, sponsors, contract research organizations (CROs), and patients. The company offers a range of products, including SureSource, an electronic source platform that facilitates the electronic capture of data and documents at clinical sites. Additionally, Clinical Ink provides Lunexis ePRO+, a technology that simplifies the implementation process and allows flexibility for patient participation. The CentrosHealth platform further engages patients through configurable applications that ensure they remain informed and compliant throughout clinical trials. Founded in 2006, Clinical Ink is headquartered in Horsham, Pennsylvania, with additional offices in North Carolina, Philadelphia, and Cambridge, Massachusetts. The company maintains a strategic alliance with CogState Limited.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for chronic conditions, particularly type 2 diabetes. The company is advancing its lead product, ITCA 650, through a phase 3 clinical program involving four separate clinical trials, aimed at providing patients with long-term stable dosing of an incretin mimetic therapy. Intarcia also offers the Medici Drug Delivery System, a subcutaneous platform designed to enhance the administration of drug therapies for various chronic diseases, including obesity and autoimmune disorders. Founded in 1997 as BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with additional facilities in Hayward, California, and a research and development center in Durham, North Carolina.
Samanage is the Service Success Company, enabling organizations worldwide to deliver a smarter service experience to their employees. Samanage’s service management software gives users solutions that allow them to deliver fast and repeatable services across an organization -- simplifying complex tasks and automating basic ones. As the most reviewed and highest rated service desk, Samanage solutions deliver insights to its users and empower them to increase productivity across their organization.
The company was founded in 2007 and is based in Cary, North Carolina. In 2019. Samanage was acquired by [SolarWinds](/organization/solarwinds).
TransEnterix, Inc. is a medical device company that focuses on the research, development, and sale of robotic systems designed to enhance minimally invasive surgery. Its primary products include the Senhance System, a multi-port robotic surgery system that utilizes multiple robotic arms for instrument control and camera operation, and the SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. These systems enable surgeons to perform complex procedures, such as gallbladder removal, with minimal scarring. TransEnterix markets its products directly and through distributors in various regions, including Europe, the United States, Japan, and Taiwan. Founded in 2006, the company is headquartered in Morrisville, North Carolina.
MediaMath, Inc. is a provider of digital advertising media and data management technology solutions for advertisers globally. The company's TerminalOne platform facilitates the activation of data, automates execution, and optimizes advertising interactions across various addressable media. Additionally, MediaMath offers an Omnichannel programmatic marketing platform that enhances personalized customer engagement, accesses media at scale, and utilizes machine learning for measurement and optimization. Beyond technology, MediaMath provides professional services in programmatic strategy, analytics, technology support, and advertising operations, as well as training and certification programs in digital marketing. Founded in 2007, MediaMath is headquartered in New York City and operates additional offices in various locations, including California, Massachusetts, Illinois, Florida, North Carolina, the United Kingdom, Spain, Germany, Singapore, Japan, Brazil, Australia, and India.
Appia is a prominent mobile user acquisition network that specializes in delivering mobile app downloads to over 1 billion users across 200 countries. The company provides a platform designed to meet the needs of mobile advertisers, ensuring a high volume of app installs and maximizing profit per install for its clients. Trusted by notable brands such as ngmoco, AppBrain, and Playtika, Appia combines a robust network with advanced technology to connect quality apps with engaged consumers. The company supports mobile application developers by offering a distribution point while providing advertisers with tools to acquire high-value customers. Appia has received $30 million in funding from various investors and has established itself as the largest non-incentivized network in the industry. With offices in San Francisco and Durham, Appia continues to evolve its product offerings and expand its network of publishers and advertisers.
MediaMath, Inc. is a provider of digital advertising media and data management technology solutions for advertisers globally. The company's TerminalOne platform facilitates the activation of data, automates execution, and optimizes advertising interactions across various addressable media. Additionally, MediaMath offers an Omnichannel programmatic marketing platform that enhances personalized customer engagement, accesses media at scale, and utilizes machine learning for measurement and optimization. Beyond technology, MediaMath provides professional services in programmatic strategy, analytics, technology support, and advertising operations, as well as training and certification programs in digital marketing. Founded in 2007, MediaMath is headquartered in New York City and operates additional offices in various locations, including California, Massachusetts, Illinois, Florida, North Carolina, the United Kingdom, Spain, Germany, Singapore, Japan, Brazil, Australia, and India.
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for chronic conditions, particularly type 2 diabetes. The company is advancing its lead product, ITCA 650, through a phase 3 clinical program involving four separate clinical trials, aimed at providing patients with long-term stable dosing of an incretin mimetic therapy. Intarcia also offers the Medici Drug Delivery System, a subcutaneous platform designed to enhance the administration of drug therapies for various chronic diseases, including obesity and autoimmune disorders. Founded in 1997 as BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with additional facilities in Hayward, California, and a research and development center in Durham, North Carolina.
Catena Networks develops broadband access systems that enable service providers to deploy voice, data, and video services. The company's products include The CNX-5 Broadband DSL System, a card-for-card upgrade solution for Lucent SLC-5 Digital Loop Carriers and The CN1000 Broadband Loop Carrier that enables service providers to deploy integrated plain old telephone service (POTS) and digital subscriber line (DSL) services and deliver voice, data and video services over copper and fiber infrastructures. It caters to local exchange carriers, postal telephone and telegraph operators, and other service providers. The company was founded in 1998 and is based in California, US with an additional office in Morrisville, North Carolina.